Sugi Predict

Sugi Predict / Targets / CDK2AP1

CDK2AP1

Cyclin-dependent kinase 2-associated protein 1 · O14519 · CDK2AP1 on Sugi Atlas →

1,665 patent compounds predicted against CDK2AP1, 1,113 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL4221627 SCHEMBL4221627 0.74 13/20
SCHEMBL1562867 SCHEMBL1562867 1.00 12/20
SCHEMBL1564283 SCHEMBL1564283 1.00 12/20
SCHEMBL1564625 SCHEMBL1564625 0.94 12/20
SCHEMBL4209764 SCHEMBL4209764 0.91 12/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL4212868) 0.90 12/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL4216049) 0.90 12/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL4223989) 0.90 12/20
SCHEMBL1564904 SCHEMBL1564904 0.82 12/20
SCHEMBL1564152 SCHEMBL1564152 0.81 12/20
SCHEMBL4212769 SCHEMBL4212769 0.81 12/20
SCHEMBL4213625 SCHEMBL4213625 0.81 12/20
SCHEMBL4213799 SCHEMBL4213799 0.81 12/20
SCHEMBL4210284 SCHEMBL4210284 0.76 12/20
SCHEMBL4221667 SCHEMBL4221667 0.76 12/20
SCHEMBL1564560 SCHEMBL1564560 0.71 12/20
SCHEMBL1564133 SCHEMBL1564133 0.68 12/20
SCHEMBL4215015 SCHEMBL4215015 0.68 12/20
SCHEMBL1563623 SCHEMBL1563623 0.67 12/20
SCHEMBL4209769 SCHEMBL4209769 0.55 12/20

Clinical trials — most relevant to CDK2AP1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) PHASE3COMPLETED
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer PHASE3ACTIVE_NOT_RECRUITING
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) PHASE1/PHASE2NOT_YET_RECRUITING
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6 PHASE2RECRUITING
Avelumab, Palbociclib and Axitinib in Advanced RCC PHASE2WITHDRAWN
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma PHASE2COMPLETED
Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast Cancer PHASE2UNKNOWN
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer PHASE2WITHDRAWN
Selective Treatment According to Molecular Subtype of Prostate Cancer PHASE2UNKNOWN
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer PHASE2COMPLETED
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression PHASE2COMPLETED
Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor PHASE2ACTIVE_NOT_RECRUITING
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer PHASE2COMPLETED
Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma PHASE1WITHDRAWN
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery PHASE1COMPLETED
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma PHASE1COMPLETED
Study of Proteins in Head and Neck Cancer Cells nanCOMPLETED
Genetic Analysis of Familial Melanoma nanCOMPLETED
The Relation of Microtubule-Associated Protein 2 and Cell Migration nanUNKNOWN
Better Delineation of CDK13 Related Phenotype and Epigenetic Signature. nanUNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Effect of Branched Chain Amino Acids on Muscle nanCOMPLETED
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period nanUNKNOWN
Mechanism and Immune Function Analysis of SARS-CoV-2 Infection in Hematologic Tumors nanACTIVE_NOT_RECRUITING
Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CDK2AP1 binder may also engage these)

ProteinNameSimilarity
P49119 — 0.996 P49119 →
O35207 — 0.995 O35207 →
Q6GZQ5 — 0.992 Q6GZQ5 →
Q9CPY4 — 0.991 Q9CPY4 →
A5U292 — 0.988 A5U292 →
Q64914 — 0.988 Q64914 →
P17523 — 0.988 P17523 →
Q58CN7 — 0.988 Q58CN7 →
Q6PF39 — 0.987 Q6PF39 →
P66722 — 0.987 P66722 →
A1KIH9 — 0.987 A1KIH9 →
P9WGY4 — 0.987 P9WGY4 →
P17524 — 0.987 P17524 →
Q6UDH8 — 0.987 Q6UDH8 →
P0CK62 — 0.987 P0CK62 →
Q1HVC7 — 0.987 Q1HVC7 →
Q5RFT9 — 0.987 Q5RFT9 →
A2R4I0 — 0.986 A2R4I0 →
Q759B7 — 0.986 Q759B7 →
P0C6K3 — 0.986 P0C6K3 →
Q14EA6 — 0.986 Q14EA6 →
Q6MW04 — 0.986 Q6MW04 →
P97588 — 0.986 P97588 →
Q4JQW6 — 0.986 Q4JQW6 →
Q05536 — 0.986 Q05536 →
Q64912 — 0.986 Q64912 →
EYA2 Protein phosphatase EYA2 0.986 landscape →
Q64845 — 0.986 Q64845 →
P09272 — 0.986 P09272 →
Q77GW1 — 0.986 Q77GW1 →